Ophthalmology Times

FDA approves Johnson & Johnson's TECNIS PureSee EDOF IOL

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...
MassDevice

Johnson & Johnson wins FDA nod for new intraocular lens

Johnson & Johnson (NYSE: JNJ) announced that it received FDA approval for its Tecnis PureSee intraocular lens (IOL) for cataract surgery.
Healio

Deferred IOL implantation leads to better outcomes in traumatic pediatric cataract

Primary IOL implantation in pediatric open globe injuries with active inflammation showed inferior visual outcomes compared ...

Johnson & Johnson Launches New TECNIS Odyssey Next-Generation Intraocular Lens in India Offering Cataract Patients Precise Vision at Every Distance in Any Lighting

Johnson & Johnson’s TECNIS Odyssey IOL launched in India, offering a full visual range and high contrast to reduce spectacle dependency.
GlobalData on MSN

FDA approves J&J’s TECNIS PureSee intraocular lens

The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.
Healio

FDA approves Johnson & Johnson’s Tecnis PureSee IOL

The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release ...
Nasdaq

Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting

The new full visual range IOL*1 delivers exceptional distance vision2 and 14% smaller readable print size vs PanOptix3 †. 93% of patients become free from glasses at all distances.#4 ‡ TECNIS Odyssey ...